Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei

2009 ◽  
Vol 99 (5) ◽  
pp. 292-295 ◽  
Author(s):  
Terence C. Chua ◽  
Tristan D. Yan ◽  
Zhu L. Yap ◽  
Matthew D. Horton ◽  
Gary G. Fermanis ◽  
...  
Keyword(s):  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei

scholarly journals Correction to: Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of highgrade pseudomyxoma peritonei

2021 ◽  
Vol 38 (2) ◽  
pp. 253-253
Author(s):  
Olaf Sørensen ◽  
Anders Mikal Andersen ◽  
Stein Gunnar Larsen ◽  
Karl‑Erik Giercksky ◽  
Kjersti Flatmark
Keyword(s):  
Experimental Model ◽  
Mitomycin C ◽  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei

Pseudomyxoma peritonei: visceral scalloping on CT is a predictor of recurrence after complete cytoreductive surgery

2020 ◽  
Vol 30 (8) ◽  
pp. 4193-4200
Author(s):  
Masatoshi Hotta ◽  
Ryogo Minamimoto ◽  
Yoshimasa Gohda ◽  
Tsuyoshi Tajima ◽  
Tomomichi Kiyomatsu ◽  
...  
Keyword(s):  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei

scholarly journals Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei

2019 ◽  
Vol 36 (6) ◽  
pp. 511-518 ◽  
Author(s):  
Olaf Sørensen ◽  
Anders Mikal Andersen ◽  
Stein Gunnar Larsen ◽  
Karl-Erik Giercksky ◽  
Kjersti Flatmark
Keyword(s):  
Mitomycin C ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei ◽  
Male Rats ◽  
High Grade ◽  
Regional Hyperthermia ◽  
Tumor Spread ◽  
Modest Improvement ◽  
Normothermic Group

Abstract Pseudomyxoma peritonei (PMP) is a rare cancer commonly originating from appendiceal neoplasms that presents with mucinous tumor spread in the peritoneal cavity. Patients with PMP are treated with curative intent by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The value of adding HIPEC to CRS has not been proven in randomized trials, and the objective of this study was to investigate the efficacy of intraperitoneal mitomycin C (MMC) and regional hyperthermia as components of this complex treatment. Xenograft tissue established from a patient with histologically high-grade PMP with signet ring cell differentiation was implanted intraperitoneally in 65 athymic nude male rats and the animals were stratified into three treatment groups; the cytoreductive surgery group (CRSG, CRS only), the normothermic group (NG, CRS and intraperitoneal chemotherapy perfusion (IPEC) with MMC at 35 ºC), and the hyperthermic group (HG, CRS and IPEC at 41 ºC). The main endpoints were survival and tumor weight at autopsy. Adequate imitation of the clinical setting and treatment approach was achieved. The median survival was 31 days in the CRSG, 60 days in NG and 67 days in HG. The median tumor weights at autopsy were 34 g in CRSG, 23 g NG and 20 g in HG. In conclusion, the addition of IPEC with MMC after CRS doubled the survival time and reduced tumor growth compared to CRS alone. Adding regional hyperthermia resulted in a modest improvement of treatment outcome.

Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei

2019 ◽  
Vol 26 (5) ◽  
pp. 1429-1436 ◽  
Author(s):  
Joal D. Beane ◽  
Gregory C. Wilson ◽  
Jeffrey M. Sutton ◽  
Yongli Shuai ◽  
Lekshmi Ramalingam ◽  
...  
Keyword(s):  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei ◽  
Intraperitoneal Chemoperfusion

Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals

Surgery Today ◽  
2011 ◽  
Vol 41 (9) ◽  
pp. 1219-1223 ◽  
Author(s):  
Toshiyuki Kitai ◽  
Masahiro Kawashima ◽  
Kenya Yamanaka ◽  
Kunio Ichijima ◽  
Hideaki Fujii ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei
Sign in / Sign up

Export Citation Format

Share Document